12 results about "Myonectin" patented technology

Provided herein are antibodies or antigen-binding fragments thereof targeting Nectin-4. Also provided herein are the uses and methods of the antibodies or antigen-binding fragments thereof, or the antibody-drug conjugates in treating cancers.

A universal biological prosthesis of acellular dermal matrix (ADM) intended for use in body reconstruction processes and method of manufacture. A universal biological prosthesis of acellular dermal matrix (ADM) intended for use in body reconstruction processes, comprising: a first layer of ADM of biological origin arranged inferiorly to delimit a cavity with a lower edge; a filling material disposed in the cavity surrounded by the first layer of ADM consisting of a ground ADM having the consistency of a fibrous paste; and a second layer of ADM of biological origin arranged on the upper part covering the filling material and whose upper edge rests peripherally on the lower edge of the first layer of ADM, thus defining a rim;where the first layer of ADM and the second layer of ADM are joined by an eyebrow overlap along the upper edge of the first layer of ADM with the lower edge of the peripheral rim using a biocompatible adhesive, or by absorbable suture; where the first layer of ADM, the second layer of ADM and the ADM filling material are not immunogenic; and where the ADM comprises collagen fibers, fibronectin, elastin, laminin, glycosaminoglycans and hyaluronic acid. Method for its manufacture.

The present application relates to the technical field of artificial dermis, and particularly relates to a preparation method and application of artificial dermis based on biomimetic acellular matrix. The artificial dermis comprises a biomimetic acellular matrix component A and an auxiliary component B, wherein the component A comprises type I collagen, type VI collagen, elastin, fibronectin, laminin, matricellular protein and dextran; the component B comprises antibacterial peptide, antibiotic and high molecular polymer material; the mass ratio of the component A to the component B is (4-6):(1-4). The preparation method comprises the steps of respectively preparing A and B component process mother liquor, step-by-step crosslinking to prepare a hydrogel with a double-layer gradient structure, and then freeze-drying and sterilization treatment. The artificial dermis has good biocompatibility and antibacterial performance, can effectively promote wound healing, and is suitable for repairing acute and chronic wounds of limbs, facial parts and trunk parts, and is particularly suitable for repairing complex wounds with exposed bones, tendons, nerves and blood vessels.

The invention is directed to a composition of soluble placental ECM in storage solution and the methods of manufacture related thereto. The solubilized placental ECM solution is manufactured through a process of partitioning placental ECM from the placental tissue in a high acidic pH environment and performing an ultrafiltration step and diafiltration step through a tangential flow filtration system to increase the pH. The soluble placental ECM retains the native characteristics of placental ECM components and includes collagens (types I, III, V, VI, IX, and X), elastin, laminin, and fibronectin.

Disclosed herein are Nectin-4 antibodies. In some embodiments, the Nectin-4 antibodies can be used in treatments such as, for example, cancer treatments.

To provide a novel composition for application on the skin of human or the like that prevents the deterioration of skin function.SOLUTION: The present invention provides a composition that comprises tranexamic acid for inhibiting the degradation of laminin 511 in the skin.SELECTED DRAWING: None

The present invention provides antigen-binding proteins capable of binding to Nectin-4 polypeptides conjugated to chemotherapeutic agents, for use in increasing sensitivity of tumors to the chemotherapeutic agents, for use in the treatment of cancers characterized by Nectin expressing tumor cells. In one embodiment, the present invention provides conjugates of an anti-Nectin-4 antibody to a camptothecin analogue, such as exatecan or SN-38, through a cleavable linker.

The objective is to provide therapeutic drugs that promote wound healing. [Solution] Analysis of Dectin-1 gene-deficient mice revealed that inhibiting Dectin-1 promotes wound healing caused by burns. When laminarin, a Dectin-1 antagonist, or barley β-glucan 30sp was administered to the wound, a significant wound healing promoting effect was observed. Since low molecular weight β-glucan, a Dectin-1 antagonist, has the effect of promoting wound healing, a wound healing promoter containing it as an active ingredient can be provided.

Provided is an antibody molecule that binds to human Nectin-4 or a fragment thereof. The antibody is obtained by means of hybridoma screening and humanization techniques, and is used for the prevention or treatment of a cancer, and may be used as a clinical lead drug molecule.

The invention discloses a lentiviral vector and an application of the lentiviral vector in preparation of a medicine for treating bordering epidermis bullosa. Compared with an existing gene therapy technology based on gamma-retrovirus for transmitting hLAMB3, the lentiviral vector has the advantages that the lentiviral vector can be used for treating bordering epidermis bullosa; when being applied and expressed in a skin tissue sheet generated by autologous keratinocytes, the screened beta3 sublaminin-5 protein expression cassette, the lentivirus transfer plasmid, the lentivirus packaging system, the lentivirus vector particles, the genetically engineered cells and the pharmaceutical composition have both safety and high efficiency.

This invention provides a complex protein composition, product, and application for improving skin condition. The complex protein composition includes type IV collagen, type VII collagen, type XVII collagen, laminin 332, and fibronectin. This complex protein composition helps to improve skin condition, delay the appearance of aging, reduce wrinkles, and improve sagging. Simultaneously, it plays a positive role in repairing and supporting the skin barrier and extracellular matrix structure, which is beneficial for maintaining the stability and orderly remodeling of the skin microenvironment.

The invention relates to a universal biological acellular dermal matrix (ADM) prosthesis for use in body reconstruction processes, comprising: a first layer of ADM of biological origin, arranged at the bottom to delimit a cavity with a bottom edge; a packing material which is arranged in the cavity surrounded by the first ADM layer and consists of ground ADM material having the consistency of a fibrous pulp; and a second layer of ADM of biological origin which is arranged on the upper part and covers the packing material and the top edge of which rests, at its periphery, on the bottom edge of the first layer of ADM, thereby defining a rim; wherein the first layer of ADM and the second layer of ADM are joined by precisely arranging the upper edge of the first layer of ADM on top of the bottom edge of the rim, at the periphery, using a biocompatible glue or using sutures made of resorbable thread; wherein the first layer of ADM, the second layer of ADM and the ADM packing material are not immunogenic; and wherein the ADM comprises collagen fibres, fibronectin, elastin, laminin, glycosaminoglycans and hyaluronic acid. The invention also relates to a method for producing same.